Specifically, the HER2+ subtype is one of the most glutamine metabolism-dependent subtypes, and the elevated levels of glutamine transporter protein (SLC1A5) and GLS transcripts in HER2+ breast cancers increased their dependence on glutamine metabolism, thus identifying new therapeutic targets for HER2+ breast cancers (Lv et al., 2022). This evidence concerns the gene SLC1A5 and breast carcinoma.